Generex Biotechnology Corporation  

(Public, OTCMKTS:GNBT)   Watch this stock  
Find more results for Brian McGee´┐Ż
-0.00060 (-7.89%)
Nov 24 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.01 - 0.01
52 week 0.01 - 0.03
Open 0.01
Vol / Avg. 300,883.00/2.38M
Mkt cap 6.01M
P/E     -
Div/yield     -
EPS 0.00
Shares 859.22M
Beta 0.80
Inst. own 0%

Key stats and ratios

Q3 (Jul '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -53.22% -56.56%
Return on average equity - -
Employees 8 -
CDP Score - -


604-555 Richmond St W
+1-416-3642551 (Phone)
+1-647-5477104 (Fax)

Website links


Generex Biotechnology Corporation is engaged in pharmaceutical and biotechnological research and development of drug delivery systems and technologies, and other activities. The Company offers a platform technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. It develops drug delivery systems and technologies for metabolic and immunological diseases. The Company is conducting pre-clinical and human clinical trials using its technology platforms in the areas of diabetes, pain management and cancers. Its buccal insulin product, Generex Oral-lyn, provides a needle-free means of delivering insulin for the patients suffering from type I diabetes and type II diabetes. Its buccal delivery technology involves the preparation of formulations in which an active pharmaceutical agent is placed in a solution with a combination of absorption enhancers and other excipients.

Officers and directors

Mark A. Fletcher Esq President, Chief Executive Officer, General Counsel, Director
Stephen Fellows Chief Financial Officer
David A. Brusegard Ph.D. Chief Operating Officer, Secretary
Eric von Hofe Ph.D. Director
Age: 59
James H. Anderson Jr,M.D. Independent Director
Age: 68
Brian T. McGee Independent Director
Age: 53